Perspective Therapeutics
CATX
Market cap $900M

13.35 USD

+0.14

1.06%

At close Oct 4, 4:00 PM EDT

After hours

13.45

+0.10

0.75%

1 day

1.06%

5 days

5.12%

1 month

-12.52%

3 months

21.81%

6 months

-10.40%

Year to date

232.92%

1 year

347.99%

5 years

317.19%

About: Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.

Employees: 119

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,728 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

30% more capital invested

Capital invested by funds: $297M [Q1] → $385M (+$88.1M) [Q2]

7.12% more ownership

Funds ownership: 50.21% [Q1] → 57.33% (+7.12%) [Q2]

0% more funds holding

Funds holding: 104 [Q1] → 104 (+0) [Q2]

0% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 51

50% less funds holding in top 10

Funds holding in top 10: 2 [Q1] → 1 (-1) [Q2]

79% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 43

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$17

27%

upside

Avg. target

$23

71%

upside

High target

$27

102%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Wedbush David Nierengarten 47% 1-year accuracy 30 / 64 met price target	87%upside $25	Outperform Initiated	1 Oct 2024
Truist Securities Nicole Germino 100% 1-year accuracy 2 / 2 met price target	57%upside $21	Buy Initiated	25 Sept 2024
RBC Capital Gregory Renza 44% 1-year accuracy 35 / 79 met price target	102%upside $27	Outperform Maintained	16 Aug 2024
Oppenheimer Jeff Jones 39% 1-year accuracy 12 / 31 met price target	27%upside $17	Outperform Maintained	13 Aug 2024
B of A Securities Alec Stranahan 0% 1-year accuracy 0 / 2 met price target	80%upside $24	Buy Initiated	25 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 3 articles about CATX published over the past 30 days

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Perspective Therapeutics, Inc. expects updated data from cohorts 1 & 2 from the phase 1/2a study, using VMT-01 for the treatment of patients with MC1R-positive metastatic melanoma, in the 2nd half of 2024. The global melanoma market is expected to grow to $13.11 billion by 2029. Clinical supply agreement made with Bristol-Myers Squibb for use of Opdivo as a checkpoint inhibitor to be combined with VMT-01 to target patients with MC1R-positive metastatic melanoma.

Perspective: VMT01/02 Melanoma Data Coming For Radiotherapeutic Proof-Of-Concept

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Shares of Perspective Therapeutics Inc (CATX, Financial) surged 3.40% in mid-day trading on Oct 2. The stock reached an intraday high of $13.10, before settling at $13.06, up from its previous close of $12.63.

Perspective Therapeutics Inc (CATX) Trading 3.4% Higher on Oct 2

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

SEATTLE, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the Company will present updated preclinical data on PSV359 at the 37th Annual Congress of the European Association of Nuclear Medicine (“EANM”), which is being held in Hamburg, Germany, from October 19-23, 2024. Presentations regarding certain of the Company's other assets, including results based on investigator-initiated use of certain of those assets, will also be made at EANM.

Perspective Therapeutics to Present at the 37th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

SEATTLE, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that the U.S. Food and Drug Administration (the “FDA”) granted Fast Track Designation for the development of 212Pb VMT01 for the diagnosis and treatment of patients with unresectable or metastatic melanoma and who have demonstrated MC1R tumor expression. Melanocortin 1 receptor, or “MC1R,” is a protein that can be overexpressed in metastatic melanoma.

Perspective Therapeutics Granted Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

SEATTLE, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming investor conferences.

Perspective Therapeutics to Participate in Upcoming Investor Conferences in September

Zacks Investment Research

Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?

Here is how Perspective Therapeutics (CATX) and Adma Biologics (ADMA) have performed compared to their sector so far this year.

Is Perspective Therapeutics, Inc. (CATX) Outperforming Other Medical Stocks This Year?

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

SEATTLE, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced second quarter financial results for the period ended June 30, 2024.

Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal 2Q 2024 Results

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will be available for one-on-one meetings with investors in the following upcoming investor conferences as well as a panel discussion as noted.

Perspective Therapeutics to Participate at Upcoming Investor Conferences in August

3 Outperforming Stocks Surpassing Even Nvidia This Year

Nvidia (NASDAQ: NVDA ) is having a fantastic year in the markets, up 156% in 2024. That follows a 2023 return of 239%.

3 Outperforming Stocks Surpassing Even Nvidia This Year

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

SEATTLE, July 22, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its second quarter 2024 financial results and provide a business update on Monday, August 12, 2024 after the market closes. The press release will be available on the newsroom section of the Company's website at https://perspectivetherapeutics.com/newsroom/press-releases.

Perspective Therapeutics to Provide Business Highlights and Report Second Quarter 2024 Financial Results

See News Rankings

Charts implemented using Lightweight Charts™